Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

tential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their agreement in respect of OGX-011 to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential surv
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... ... information company that develops and supplies irrigation management solutions. The company was approved for ... irrigation management control where “the plant is the sensor™.” , ... (Vocus) April 30, 2010 -- ...
... BEACH, California , and AMSTERDAM , April ... Meeting of the American Society of Breast,Surgeons, Agendia, a ... Research and Treatment has published an important study,demonstrating the ... breast cancer recurrence according to the MammaPrint test. The,ASBS ...
... April 29  Scotland will showcase the ... the world,s leading pharma and biotech companies to its ... in Chicago .  Heading into the conference, ... the nation,s unique integrated industry approach will continue to ...
Cached Biology Technology:$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy 2New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 2Scotland Announces New Life Science Leadership and Investments at BIO 2010 3Scotland Announces New Life Science Leadership and Investments at BIO 2010 4
(Date:7/9/2014)... July 9, 2014Biofuels derived from the oils produced by ... fuels. To achieve this goal, optimization of cost effective ... pond systems, is needed. Sapphire Energy has developed an ... pond algae cultivation systems, described in Industrial Biotechnology ... publishers. The article is available on the Industrial ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... era of increasing concern about the prevalence of ... a promising new pathway to disabling disease: blocking ... The scientists showed how bacterial siderophore, a small ... to fan bacterial growth as well as ... this infection process. Their findings appear in a ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Bacteria hijack plentiful iron supply source to flourish 2
... American Societies for Experimental Biology (FASEB) announces the opening ... DNA in Mammalian Genomes. Mobile elements have been ... and altering functions within mammalian genomes, and continue to ... explosion of data from high throughput sources, as well ...
... prepared a patient to inhale a panic-inducing dose of carbon ... the mixture, she cried for help, overwhelmed by the sensation ... her 40s known as SM, has an extremely rare condition ... amygdala, an almond-shaped area in the brain long known for ...
... for Experimental Biology (FASEB) announces the opening of registration ... and Flagella. The 2013 Biology of Cilia ... conference where basic and translational research intersect to drive ... ciliopathies. The underlying theme of the 2013 conference is ...
Cached Biology News:Human brain is divided on fear and panic 2Human brain is divided on fear and panic 3
... life easier. It offers a wide array of features ... *Instruments supported: ... XP, PR, SR, PG-S, PG, SG, AT, MT, UMT, ... User guidance on the balance display ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
ZBP-89 (S-15)...
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
Biology Products: